Vigil Neuroscience (VIGL) shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi (SNY).

Sanofi agreed to pay $8.00 per share in cash at closing, a significant premium over Vigil's closing price of $2.31 on Wednesday, for a total of $470 million. The company will pay an additional $2.00 per share in cash if Vigil's Alzheimer's drug, VG-3927, achieves commercial sales, which would bring the total to $600 million. The deal is expected to close in the third quarter of 2025. 

VG-3927 is a 澳洲幸运5官方开奖结果体彩网:Phase 2-ready clinical candiಞdate for potential✃ treatment of Alzheimer's disease, Vigil said.

U.S.-listed shares of Sanofi edged lower in recent trading T🐷hursday. The stock is up nearly 10% in 2025 so far.